MedCity News has partnered with BioCrossroads to provide coverage focused on Indiana’s next generation of growth and innovation in life sciences
Abnormal protein phosphorylation is viewed as a trigger of most cancers, Alzheimer’s disease and Parkinson’s,
Purdue spinout Tymora Analytical Operations is using the analysis of protein phosphorylation as a platform for building out clinical research tools for drug discovery – and ultimately for diagnostics, said Anton Iliuk, Tymora’s chief technological officer.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
“Being able to detect these modifications allows you to find the cause of disease progression, and also find the drugs to target and fix this particular protein change,” he said.
The Indiana startup’s building a source of revenue from its clinical R&D products – it sells reagents that help researchers analyze the protein phosphorylation that occurs in a number of diseases, particularly cancer. Tymora’s tools are meant to help with the drug discovery process – helping biotechs screen drugs before they hit clinical trials.
Tymora is hoping to leverage any success from its R&D tool platform into a new set of diagnostics, which examines the protein phosphorylation patterns in a wide range of disease, Iliuk said.
“For now, that’s further away,” he said. “So the focus now is research.”
Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
The startup has some SBIR funding, as well as from the NIH and NSF, and has been bringing in revenue from the clinical research kits since 2012 – but hasn’t raised any venture funding.
Here’s how it works.